Organoid Clinical Trial against CoVID-19, page-62

Organoids derived from human pluripotent stem cells are interesting models to study mechanisms of morphogenesis and promising platforms for disease modeling and drug screening. However, they mostly remain incomplete as they lack stroma, tissue resident immune cells and in particular vasculature, which create important niches during development and disease. We propose, that the directed incorporation of mesodermal progenitor cells (MPCs) into organoids will overcome the aforementioned limitations.

https://www.nature.com/articles/s41598-019-52204-7

I find it interesting that the term “ incomplete “ was used by Sam in discussion with Tandax . Maybe the above provides some insight as to its context when conducting organoid tests . Maybe one does not test complete until it is proven in incomplete test results first , there may be multiple reasons for this , time , cost , etc .
The one thing it would be safe to assume , fail an incomplete test and I doubt they would continue and conduct further complete testing , are we now conducting complete organoid tests ? If so , it could be a very positive sign .

All in my opinion......